首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 156 毫秒
1.
血液中的循环肿瘤细胞(CTCs)与癌症转移密切相关,对CTCs进行检测有利于实现癌症早期诊断。但由于血液中CTCs个数稀少且存在异质性,因此急需发展血液中CTCs的高效分离及检测方法。此外,释放被捕获的细胞并进行后续培养及基因水平分析,将会进一步推进癌症的个性化治疗。本文综述了近年来CTCs捕获及释放的相关研究进展,并展望了其应用前景及发展方向。  相似文献   

2.
循环肿瘤细胞(CTCs)是肿瘤研究和临床癌症诊断中的重要对象,也是"液体活检"的重要标志物.CTCs携带着肿瘤组织的遗传和表型信息,有助于肿瘤的早期诊断、个体化治疗和预后监测.然而,CTCs是一种极其罕见的细胞群体,在癌症患者外周血中十分稀少,这对从患者血液中分离CTCs并无损释放进行下游分析提出了挑战.目前,基于CT...  相似文献   

3.
刘路宽  杨开广  梁振  张丽华  张玉奎 《色谱》2019,37(4):358-366
血液中的循环肿瘤细胞(CTCs)携带着肿瘤组织的遗传和表型信息,是液体活检的重要标志物。监测和分析血液中CTCs的数量和性质对癌症的早期诊断、治疗方案的确定和疗效评估具有重要意义。然而CTCs在血液中的含量极低,实现对CTCs的捕获与检测极具挑战。该文综述了基于生物物理原理、生物亲和原理以及人工抗体的CTCs捕获方法,并从捕获效率、捕获纯度和释放活性保持等方面进行了评述。此外,该文还对CTCs捕获方法的发展趋势进行了展望。  相似文献   

4.
循环肿瘤细胞(CTCs)出现于癌症患者的外周血中,是一种重要的游离态组织样本,对于癌症的早期诊断和预后评估具有非常重要的临床诊断价值。由于血液中CTCs含量极少,对其进行分选富集是CTCs检测和分析的一个重要预处理步骤。传统的宏观方法虽然也能实现细胞分离,但存在耗时长、样品需求量大、目标细胞损失严重及硬件设备依赖性高等不足。近年来兴起的微流控技术可在微米尺度范围内集成物理、化学及生物手段,易于实现整体器件的微型化和低成本便携式发展,为稀有CTCs的高灵敏度、高效分选提供重要的潜在技术手段。本文综述了微流控技术实现CTCs分选的最新研究进展,详细阐述了各种被动、主动分选方法的原理及成功应用实例,分析各方法的优缺点,提出一种新型的多级分选芯片结构,并最后探讨了微流控CTCs分选芯片在临床应用中面临的挑战及未来的发展趋势。  相似文献   

5.
包建民  王丹丹  李优鑫 《色谱》2017,35(1):129-137
癌症作为常见病正严重威胁着我国乃至全球居民的健康。循环肿瘤细胞(CTCs)是一类由癌变部位释放并进入血液中的癌细胞,其在癌症的早期诊断、个体化及肿瘤转移机制研究等方面的作用正逐渐被发现和认可,但由于血液中的CTCs含量极少,对其分选极具挑战。微流控芯片作为一种微型化、高通量、集成化平台,在CTCs研究中彰显了独特的优势,相关报道也越来越多。随着研究的深入,微流控芯片技术不再局限于基于模型样品的方法学开发,而是更注重于能否用于临床实际样品中CTCs的检测,但目前未见该角度的综述报道。为此,文章综述了近年来用于临床实际样品CTCs分析的微流控芯片分选技术,并探讨了微流控芯片用于CTCs分选的发展趋势。  相似文献   

6.
循环肿瘤细胞(Circulating tumor cells,CTCs)的简单、快速分离和检测是目前临床研究中面临的一项挑战.本研究制备了具有肿瘤靶向识别作用的磁性荧光IR780-Fe3 O4纳米颗粒,并将其用于CTCs的分离和检测.通过电镜、荧光光谱仪和超导量子干涉仪对合成的IR780-Fe3 O4纳米颗粒进行表征;采用激光共聚焦显微镜和流式细胞仪对IR780-Fe3 O4纳米颗粒对肿瘤细胞和正常细胞的靶向效果进行了分析;利用激光共聚焦显微镜对IR780-Fe3 O4纳米颗粒在MCF-7细胞中的位置进行定位;并根据IR780-Fe3 O4纳米颗粒孵育后肿瘤细胞的荧光强度绘制标准曲线.研究结果表明,IR780-Fe3 O4能很好地靶向多种CTCs.细胞定位实验进一步表明,IR780-Fe3 O4主要靶向识别肿瘤细胞的线粒体.通过Fe3 O4磁性纳米颗粒偶联IR780建立的这种方法可很好地区分肿瘤细胞和正常细胞,并对模拟血液中的CTCs进行了分离和检测.  相似文献   

7.
郭珊  周翔 《化学进展》2021,33(1):1-12
从实体瘤脱落进入血液循环系统的肿瘤细胞即循环肿瘤细胞(CTCs)与肿瘤转移密切相关,因此CTCs检测对癌症患者的诊断、治疗监测、病情评估以及肿瘤转移机制研究具有重要意义。由于CTCs在体内含量极少、异质性、分布不均一,通过体外采血发展的CTCs检测技术虽然已取得很大进展,但仍然面临肿瘤细胞损失、失活、失真以及灵敏度低等问题,因此亟需发展基于体内快速流动血液的肿瘤细胞检测技术,在真实生理状态下实时监测CTCs动态变化。在此,我们总结了CTCs体内检测技术及其相关应用的研究进展,分析了这些技术的优势和不足。最后,讨论并展望了CTCs体内检测技术的未来发展趋势。  相似文献   

8.
纳米生物无机界面的研究是无机化学学科新兴的前沿领域之一。纳米结构的无机材料在仿生界面、细胞界面、生物检测界面等领域扮演着越来越重要的角色。近几年来,无机纳米结构被尝试用于痕量循环肿瘤细胞(Circulating Tumor Cells,CTCs)分离的基础探索研究中,并展现出非常吸引人的应用前景。痕量CTCs的高效分离对于癌症早期检测、术后监测及生物学研究等具有重要的意义。本文主要综述纳米生物无机界面在CTCs分离中的应用,详细介绍其发展现状,并对未来做一展望。  相似文献   

9.
纳米生物无机界面的研究是无机化学学科新兴的前沿领域之一。纳米结构的无机材料在仿生界面、细胞界面、生物检测界面等领域扮演着越来越重要的角色。近几年来, 无机纳米结构被尝试用于痕量循环肿瘤细胞(Circulating Tumor Cells, CTCs)分离的基础探索研究中, 并展现出非常吸引人的应用前景。痕量CTCs的高效分离对于癌症早期检测、术后监测及生物学研究等具有重要的意义。本文主要综述纳米生物无机界面在CTCs分离中的应用, 详细介绍其发展现状, 并对未来做一展望。  相似文献   

10.
杜晶辉  刘旭  徐小平 《色谱》2014,32(1):7-12
近年来,循环肿瘤细胞(CTCs)研究得到了越来越多的关注,许多研究报告已经证实其在肿瘤转移的早期诊断、治疗方案选择、个体化治疗及探索肿瘤转移机制等方面具有潜在的价值,然而CTCs在循环系统中的含量极低,这成为限制其临床相关应用的主要难点。微流控芯片技术具有低成本、快速、高通量及操作简单等优势,利用微流控芯片可实现CTCs的高速、高回收率、高纯度的分选富集,近年来得到广泛的关注。本文综述了近年来在微流控芯片内进行CTCs分选富集的研究并探讨了各种方法的优缺点,并在本研究团队的研究基础上进行了展望。  相似文献   

11.
The prognosis of malignant tumors is challenged by insufficient means to effectively detect tumors at early stage. Liquid biopsy using circulating tumor cells (CTCs) as biomarkers demonstrates a promising solution to tackle the challenge, because CTCs play a critical role in cancer metastatic process via intravasation, circulation, extravasation, and formation of secondary tumor. However, the effectiveness of the solution is compromised by rarity, heterogeneity, and vulnerability associated with CTCs. Among a plethora of novel approaches for CTC isolation and enrichment, microfluidics leads to isolation and detection of CTCs in a cost-effective and operation-friendly way. Development of microfluidics also makes it feasible to model the cancer metastasis in vitro using a microfluidic system to mimick the in vivo microenvironment, thereby enabling analysis and monitor of tumor metastasis. This paper aims to review the latest advances for exploring the dual-roles microfluidics has played in early cancer diagnosis via CTC isolation and investigating the role of CTCs in cancer metastasis; the merits and drawbacks for dominating microfluidics-based CTC isolation methods are discussed; biomimicking cancer metastasis using microfluidics are presented with example applications on modelling of tumor microenvironment, tumor cell dissemination, tumor migration, and tumor angiogenesis. The future perspectives and challenges are discussed.  相似文献   

12.
Circulating tumor cells (CTCs) are an important biomarker for cancer prognosis and treatment monitoring. However, the heterogeneity of the physical and biological properties of CTCs limits the efficiency of various approaches used to isolate small numbers of CTCs from billions of normal blood cells. To address this challenge, we developed a lateral filter array microfluidic (LFAM) device to integrate size‐based separation with immunoaffinity‐based CTC isolation. The LFAM device consists of a serpentine main channel, through which most of a sample passes, and an array of lateral filters for CTC isolation. The unique device design produces a two‐dimensional flow, which reduces nonspecific, geometric capture of normal cells as typically observed in vertical filters. The LFAM device was further functionalized by immobilizing antibodies that are specific to the target cells. The resulting devices captured pancreatic cancer cells spiked in blood samples with (98.7±1.2) % efficiency and were used to isolate CTCs from patients with metastatic colorectal cancer.  相似文献   

13.
Bhagat AA  Hou HW  Li LD  Lim CT  Han J 《Lab on a chip》2011,11(11):1870-1878
Blood is a highly complex bio-fluid with cellular components making up >40% of the total volume, thus making its analysis challenging and time-consuming. In this work, we introduce a high-throughput size-based separation method for processing diluted blood using inertial microfluidics. The technique takes advantage of the preferential cell focusing in high aspect-ratio microchannels coupled with pinched flow dynamics for isolating low abundance cells from blood. As an application of the developed technique, we demonstrate the isolation of cancer cells (circulating tumor cells (CTCs)) spiked in blood by exploiting the difference in size between CTCs and hematologic cells. The microchannel dimensions and processing parameters were optimized to enable high throughput and high resolution separation, comparable to existing CTC isolation technologies. Results from experiments conducted with MCF-7 cells spiked into whole blood indicate >80% cell recovery with an impressive 3.25 × 10(5) fold enrichment over red blood cells (RBCs) and 1.2 × 10(4) fold enrichment over peripheral blood leukocytes (PBL). In spite of a 20× sample dilution, the fast operating flow rate allows the processing of ~10(8) cells min(-1) through a single microfluidic device. The device design can be easily customized for isolating other rare cells from blood including peripheral blood leukocytes and fetal nucleated red blood cells by simply varying the 'pinching' width. The advantage of simple label-free separation, combined with the ability to retrieve viable cells post enrichment and minimal sample pre-processing presents numerous applications for use in clinical diagnosis and conducting fundamental studies.  相似文献   

14.
Circulating tumor cells (CTCs) present in the bloodstream are strongly linked to the invasive behavior of cancer; therefore, their detection holds great significance for monitoring disease progression. Currently available CTC isolation tools are often based on tumor-specific antigen or cell size approaches. However, these techniques are limited due to the lack of a unique and universal marker for CTCs, and the overlapping size between CTCs and regular blood cells. Dielectrophoresis (DEP), governed by the intrinsic dielectric properties of the particles, is a promising marker-free, accurate, fast, and low-cost technique that enables the isolation of CTCs from blood cells. This study presents a continuous flow, antibody-free DEP-based microfluidic device to concentrate MCF7 breast cancer cells, a well-established CTC model, in the presence of leukocytes extracted from human blood samples. The enrichment strategy was determined according to the DEP responses of the corresponding cells, obtained in our previously reported DEP spectrum study. It was based on the positive-DEP integrated with hydrodynamic focusing under continuous flow. In the proposed device, the parylene microchannel with two inlets and outlets was built on top of rectangular and equally spaced isolated planar electrodes rotated certain degree relative to the main flow (13°). The recovery of MCF7 cells mixed with leukocytes was 74%–98% at a frequency of 1 MHz and a magnitude of 10–12 Vpp. Overall, the results revealed that the presented system successfully concentrates MCF7 cancer cells from leukocytes, ultimately verifying our DEP spectrum study, in which the enrichment frequency and separation strategy of the microfluidic system were determined.  相似文献   

15.
Moon HS  Kwon K  Kim SI  Han H  Sohn J  Lee S  Jung HI 《Lab on a chip》2011,11(6):1118-1125
Circulating tumor cells (CTCs) are highly correlated with the invasive behavior of cancer, so their isolations and quantifications are important for biomedical applications such as cancer prognosis and measuring the responses to drug treatments. In this paper, we present the development of a microfluidic device for the separation of CTCs from blood cells based on the physical properties of cells. For use as a CTC model, we successfully separated human breast cancer cells (MCF-7) from a spiked blood cell sample by combining multi-orifice flow fractionation (MOFF) and dielectrophoretic (DEP) cell separation technique. Hydrodynamic separation takes advantage of the massive and high-throughput filtration of blood cells as it can accommodate a very high flow rate. DEP separation plays a role in precise post-processing to enhance the efficiency of the separation. The serial combination of these two different sorting techniques enabled high-speed continuous flow-through separation without labeling. We observed up to a 162-fold increase in MCF-7 cells at a 126 μL min(-1) flow rate. Red and white blood cells were efficiently removed with separation efficiencies of 99.24% and 94.23% respectively. Therefore, we suggest that our system could be used for separation and detection of CTCs from blood cells for biomedical applications.  相似文献   

16.
17.
Here we describe a combined microfluidic-micromagnetic cell separation device that has been developed to isolate, detect and culture circulating tumor cells (CTCs) from whole blood, and demonstrate its utility using blood from mammary cancer-bearing mice. The device was fabricated from polydimethylsiloxane and contains a microfluidic architecture with a main channel and redundant 'double collection' channel lined by two rows of dead-end side chambers for tumor cell collection. The microdevice design was optimized using computational simulation to determine dimensions, magnetic forces and flow rates for cell isolation using epithelial cell adhesion molecule (EpCAM) antibody-coated magnetic microbeads (2.8 μm diameter). Using this device, isolation efficiencies increased in a linear manner and reached efficiencies close to 90% when only 2 to 80 breast cancer cells were spiked into a small volume (1.0 mL) of blood taken from wild type mice. The high sensitivity visualization capabilities of the device also allowed detection of a single cell within one of its dead-end side chambers. When blood was removed from FVB C3(1)-SV40 T-antigen mammary tumor-bearing transgenic mice at different stages of tumor progression, cells isolated in the device using anti-EpCAM-beads and magnetically collected within the dead-end side chambers, also stained positive for pan-cytokeratin-FITC and DAPI, negative for CD45-PerCP, and expressed SV40 large T antigen, thus confirming their identity as CTCs. Using this isolation approach, we detected a time-dependent rise in the number of CTCs in blood of female transgenic mice, with a dramatic increase in the numbers of metastatic tumor cells appearing in the blood after 20 weeks when tumors transition to invasive carcinoma and exhibit increased growth of metastases in this model. Importantly, in contrast to previously described CTC isolation methods, breast tumor cells collected from a small volume of blood removed from a breast tumor-bearing animal remain viable and they can be easily removed from these devices and expanded in culture for additional analytical studies or potential drug sensitivity testing.  相似文献   

18.
The detection of circulating tumor cells (CTCs) in blood is crucial to assess metastatic progression and to guide therapy. Dielectrophoresis (DEP) is a powerful cell surface marker-free method that allows intrinsic dielectric properties of suspended cells to be exploited for CTC enrichment/isolation from blood. Design of a successful DEP-based CTC enrichment/isolation system requires that the DEP response of the targeted particles should accurately be known. This paper presents a DEP spectrum method to investigate the DEP spectra of cells without directly analyzing their membrane and cytoplasmic properties in contrast to the methods in literature, which employ theoretical assumptions and complex modeling. Integrating electric field simulations based on DEP theory with the experimental data enables determination of the DEP spectra of leukocyte subpopulations, polymorphonuclear and mononuclear leukocytes, and MCF7 breast cancer cells as a model of CTC due to their metastatic origin over the frequency range 100 kHz–50 MHz at 10 Vpp. In agreement with earlier findings, differential DEP responses were detected for mononuclear and polymorphonuclear leukocytes due to the richness of the cell surface features and morphologies of the different leukocyte types. The data reveal that the strength of the DEP force exerted on MCF7 cells was particularly high between 850 kHz and 20 MHz. These results illustrate that the proposed technique has the potential to provide a generic platform to identify DEP responses of different biological particles.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号